This episode of Lung Cancer Considered covers recent promising results with new targeted agents for NSCLC harboring a KRAS G12C mutation. Thoracic oncologists have long thought this condition was undruggable, but results presented at WCLC 2020 from the CodeBreak 100 trial provide hope that new therapies will be more readily available.

KRAS G12C Mutation with Dr. Tetsuya Mitsudomi

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Science

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Share KRAS G12C Mutation with Dr. Tetsuya Mitsudomi

Sign up to save your podcasts

KRAS G12C Mutation with Dr. Tetsuya Mitsudomi

KRAS G12C Mutation with Dr. Tetsuya Mitsudomi

More shows like Lung Cancer Considered

Freakonomics Radio

NEJM This Week

JAMA Clinical Reviews

Hidden Brain

The NPR Politics Podcast

ASCO Daily News

The Curbsiders Internal Medicine Podcast

Core IM | Internal Medicine Podcast

The Peter Attia Drive

Harrison's PodClass: Internal Medicine Cases and Board Prep

The Curious Clinicians

People I (Mostly) Admire

Conversations in Lung Cancer Research

The Weekly Show with Jon Stewart

Two Onc Docs